Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

[Ki-67 and cyclin A--prognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine].

Ahlin C, Fernö M, Amini RM, Tolockiene E, Blomqvist C, Bergh J, Fjällskog ML.

Lakartidningen. 2010 Mar 10-16;107(10):672-5. Review. Swedish. No abstract available.

PMID:
20402250
2.

Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas.

Bukholm IR, Bukholm G, Holm R, Nesland JM.

J Clin Pathol. 2003 May;56(5):368-73.

3.

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier MA, Thivat E, Mishellany F, Gimbergues P, Durando X.

Oncologist. 2008 Dec;13(12):1235-45. doi: 10.1634/theoncologist.2008-0073.

4.

Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?

Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C.

Histopathology. 2007 Oct;51(4):491-8.

PMID:
17711446
5.

Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients.

Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, Rauh C, Jud S, Schrauder M, Loehberg CR, Beckmann MW, Hartmann A, Lux MP.

Breast. 2009 Apr;18(2):135-41. doi: 10.1016/j.breast.2009.02.009.

PMID:
19342238
6.

Proliferation marker Ki-67 in early breast cancer.

Urruticoechea A, Smith IE, Dowsett M.

J Clin Oncol. 2005 Oct 1;23(28):7212-20. Review.

PMID:
16192605
7.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391.

PMID:
19380449
8.

Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Hrushesky WJ, Retsky M, Baum M, Demicheli R.

J Natl Cancer Inst. 2007 Jul 4;99(13):1053; author reply 1053-4. No abstract available.

9.

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS; International Breast Cancer Study Group..

J Natl Cancer Inst. 2008 Feb 6;100(3):207-12. doi: 10.1093/jnci/djm289.

10.

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A.

Breast Cancer Res. 2006;8(3):R31.

11.

Comparative validation of the SP6 antibody to Ki67 in breast cancer.

Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, A'Hern R, Dowsett M.

J Clin Pathol. 2010 Sep;63(9):800-4. doi: 10.1136/jcp.2010.077578.

PMID:
20671052
12.

The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.

Koda M, Sulkowska M, Kanczuga-Koda L, Tomaszewski J, Kucharczuk W, Lesniewicz T, Cymek S, Sulkowski S.

Oncol Rep. 2007 Jul;18(1):113-9.

PMID:
17549355
13.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

14.

Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67.

Engellau J, Persson A, Bendahl PO, Akerman M, Domanski HA, Bjerkehagen B, Lilleng P, Weide J, Rydholm A, Alvegård TA, Nilbert M.

Virchows Arch. 2004 Sep;445(3):224-30.

PMID:
15309631
15.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G; IMPACT Trialists Group..

J Natl Cancer Inst. 2007 Jan 17;99(2):167-70.

17.

Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.

Mehdipour P, Pirouzpanah S, Sarafnejad A, Atri M, Shahrestani ST, Haidari M.

Cell Biol Int. 2009 Oct;33(10):1050-6. doi: 10.1016/j.cellbi.2009.06.016.

PMID:
19555767
18.

Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.

Aas T, Geisler S, Helle H, Børresen-Dale AL, Lønning PE, Akslen LA.

Oncol Rep. 2005 Mar;13(3):525-30.

PMID:
15706428
19.

A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer.

Mu K, Li L, Yang Q, Yun H, Kharaziha P, Ye DW, Auer G, Lagercrantz SB, Zetterberg A.

Ann Diagn Pathol. 2015 Aug;19(4):243-8. doi: 10.1016/j.anndiagpath.2015.05.002.

PMID:
26049669
20.

Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.

Schmitz KJ, Otterbach F, Callies R, Levkau B, Hölscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA.

Mod Pathol. 2004 Jan;17(1):15-21.

Items per page

Supplemental Content

Support Center